Table 2 Trials investigating targeted therapy in advanced HCC
Trial name/identifier | Patient no. | Study type | Line | Interventions | Primary endpoint | Study status |
|---|---|---|---|---|---|---|
IMbrave150/ NCT03434379 | 480 | Phase III | First | Atezolizumab + bevacizumab vs Sorafenib | OS, PFS | Completed |
ZGDH3/NCT02645981 | 668 | Phase II/III | First | Donafenib vs sorafenib | OS | Completed |
HIMALYYA/ NCT03298451 | 1310 | Phase III | First | Durvalumab + tremelimumab vs sorafenib | OS | Ongoing |
RATIONALE-301 / NCT03412773 | 674 | Phase III | First | Tislelizumab vs sorafenib | OS | Ongoing |
PHOCUS | 600 | Phase III | First | Pexa-Vec + sorafenib vs sorafenib | OS | Ongoing |
NCT04344158 | 648 | Phase III | First | AK105 + anlotinib vs sorafenib | OS | Ongoing |
ALTER0802/ NCT02809534 | 60 | Phase II | First | Anlotinib | PFS 12W | Ongoing |
AHELP/NCT02329860 | 400 | Phase III | Second | Apatinib vs placebo | OS | Completed |
KEYNOTE-394 / NCT03062358 | 450 | Phase III | Second | Pembrolizumab + BSC vs placebo + BSC | OS | Ongoing |
NCT04080154 | 28 | Phase II | Second | Anlotinib | PFS | Ongoing |
